ALZpath, a Carlsbad, CA-based developer of innovative diagnostic solutions for Alzheimer’s disease, received a funding of undisclosed amount.
The Alzheimer’s Drug Discovery Foundation (ADDF)’s Diagnostics Accelerator made the investment.
Led by Chief Scientific Officer and principal investigator Dr. Andreas Jeromin, ALZpath is a provider of innovative diagnostic solutions for Alzheimer’s disease.
The company intends to use the funds to accelerate the analytical and clinical validation of ALZpathDx, a proprietary assay for quantifying phosphorylated tau 217 (pTau217), a highly accurate diagnostic biomarker for Alzheimer’s disease. This investment will enable ALZpath to continue generating clinical evidence and to launch an LDT version of the assay as ALZpathDx. The ALZpath pTau217 assay is currently available for research use only (RUO) through Quanterix, as a kit and for services in the Quanterix Accelerator laboratory.
FinSMEs
18/07/2023